GenomeWeb

NEW YORK – Lung cancer patients with HER2 mutations lived longer without disease progression and more saw their tumors shrink with AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu (trastuzumab deruxtecan) than they did with Merck’s checkpoint inhibitor Keytruda (pembrolizumab) and chemotherapy in a Phase III trial.

NEW YORK – SplashBio is betting on growing interest in biomarkers within Alzheimer’s disease drug development to fuel its launch as a new company.

Jessica Kim Cohen covers precision medicine at GenomeWeb, including advancements in cardiology, neurology, and rare diseases. Before joining GenomeWeb in 2022, she covered technology at Modern Healthcare magazine. Jessica sits on the national governing board of the Asian American Journalists Association and lives in Chicago. She graduated from Johns Hopkins University.

NEW YORK – A City of Hope-led research team has developed a liquid biopsy-based composite score to detect early-stage pancreatic ductal adenocarcinoma (PDAC), including an advanced precancerous condition known as high-grade dysplasia.

NEW YORK – Precure, a new company launched this week by Mayo Clinic and Thermo Fisher Scientific, aims to build a multiomic and clinical dataset spanning roughly one million biospecimens collected from patients in the Mayo network.

NEW YORK – A team led by researchers at Queen Mary University of London has used proteomic profiling of patient serum samples to help diagnose rare diseases in patients participating in Genomics England’s 100,000 Genomes Project.

NEW YORK — Clinical diagnostics firm Retham Technologies said on Tuesday that it has raised $1.5 million in seed funding.

NEW YORK - Three companies made moves in the in vivo CAR T space early this week, two starting new Phase I trials in blood cancer and another licensing a promising asset from China.

NEW YORK – Oxford Nanopore Technologies on Wednesday obtained a preliminary injunction against MGI Tech from the Munich Local Division of the European Union’s Unified Patent Court (UPC), restricting the firm from manufacturing and selling its CycloneSeq nanopore sequencers and related products in several European countries.